An overview of nanotechnology-based treatment approaches against Helicobacter Pylori

References

• Sutton P, Mitchell H. Helicobacter pylori in the 21st Century. Vol. 17. CABI; 2010:1–12.
   Google Scholar
• Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34–42.
   PubMed Web of Science ®Google Scholar
• Lopes D, Nunes C, Martins MCL, et al. Eradication of Helicobacter pylori: past, present and future. J Control Release. 2014;189:169–186.
   PubMed Web of Science ®Google Scholar
• Bagirova M, Allahverdiyev AM, Abamor ES, et al. An overview of challenges to eradication of Helicobacter pylori infection and future prospects. Eur Rev Med Pharmacol Sci. 2017;21(9):2199–2219.
   PubMed Web of Science ®Google Scholar
• Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–490.
   PubMed Web of Science ®Google Scholar
• Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis. 2017;30(5):489–497.
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239.
   Web of Science ®Google Scholar
• Den Hoed CM, Vila AJ, Holster IL, et al. Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood. Helicobacter. 2011;16(5):405–409.
   PubMed Web of Science ®Google Scholar
• Porras C, Nodora J, Sexton R, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2013;24(2):209–215.
   PubMed Web of Science ®Google Scholar
• Bastos J, Carreira H, La Vecchia C, et al. Childcare attendance and Helicobacter pylori infection: systematic review and meta-analysis. Eur J Cancer Prev. 2013;22(4):311–319.
   PubMed Web of Science ®Google Scholar
• Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol. 2007;21(2):205–214.
   PubMed Web of Science ®Google Scholar
• Dorji D, Dendup T, Malaty HM, et al. Epidemiology of helicobacter pylori in Bhutan: The role of environment and geographic location. Helicobacter. 2014;19(1):69–73.
   PubMed Web of Science ®Google Scholar
• Iwańczak BM, Buchner AM, Iwańczak F. Clinical differences of Helicobacter pylori infection in children. Adv Clin Exp Med. 2017;26(7):1131–1136.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhu Y, Lu N-H. Primary antibiotic resistance of Helicobacter pylori in China. Dig Dis Sci. 2017;62(5):1146–1154.
   PubMed Web of Science ®Google Scholar
• Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol. 2015;5(3):164.
   PubMedGoogle Scholar
• Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1994;6(9):773–778.
   Web of Science ®Google Scholar
• Gumurdulu Y, Serin E, Özer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol. 2004;10(5):668.
   PubMed Web of Science ®Google Scholar
• McColl KE. Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597–1604.
   PubMed Web of Science ®Google Scholar
• Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14(35):5385.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1): 51–69. e14.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liang X, Zheng Q, et al. High efficacy of 14 day triple therapy based, bismuth containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233–238.
   PubMed Web of Science ®Google Scholar
• Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101(3):488.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136(1):13–24.
   PubMed Web of Science ®Google Scholar
• Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori–infected persons, United States. Emerg Infect Dis. 2004;10(6):1088–1094.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007;45(12):4006–4010.
   Web of Science ®Google Scholar
• Morilla AM, Álvarez-Argüelles ME, Duque JM, et al. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterologia y hepatologia; 2019;42(8):476–485.
   Google Scholar
• Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–533.
   PubMed Web of Science ®Google Scholar
• Mosites E, Bruden D, Morris J, et al. Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000–2016. J Glob Antimicrob Resist. 2018;15:148–153.
   PubMed Web of Science ®Google Scholar
• Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Clin Pract Gastroenterol Hepatol. 2017;14(7):383.
   Google Scholar
• Aygül A. The importance of efflux systems in antibiotic resistance and efflux pump inhibitors in the management of resistance. Mikrobiyoloji Bulteni. 2015;49(2):278–291.
   PubMed Web of Science ®Google Scholar
• Kristiansen J, Thomsen VF, Martins A, et al. Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo. 2010;24(5):751–754.
   PubMed Web of Science ®Google Scholar
• Li P, Chen X, Shen Y, et al. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release. 2019;300:52–63.
   PubMed Web of Science ®Google Scholar
• Holten KB. Appropriate prescribing of oral beta-lactam antibiotics. Am Fam Physician. 2000;62(3).
   PubMed Web of Science ®Google Scholar
• Bayerdorffer E, Mannes GA, Sommer A, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol. 1992;4(9):697–702.
   Web of Science ®Google Scholar
• Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus metronidazole as first-line helicobacter pylori eradication. J Clin Gastroenterol. 2015;49(6):468–471.
   PubMed Web of Science ®Google Scholar
• Yilmaz Ö, Demiray E. Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. World J Gastroenterol. 2007;13(5):671.
   PubMed Web of Science ®Google Scholar
• Goodwin A, Kersulyte D, Sisson G, et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen‐insensitive NADPH nitroreductase. Mol Microbiol. 1998;28(2):383–393.
   PubMed Web of Science ®Google Scholar
• Mohanraj V, Chen Y. Nanoparticles-a review. Trop J Pharm Res. 2006;5(1):561–573.
   Google Scholar
• Bhatia S Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. In: Natural polymer drug delivery systems. Springer, Cham; 2016. p. 33–93.
   Google Scholar
• Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arabian J Chem. 2017.
   Web of Science ®Google Scholar
• Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2013;65(1):21–23.
   PubMed Web of Science ®Google Scholar
• Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289.
   PubMed Web of Science ®Google Scholar
• Lotfipour F, Valizadeh H, Milani M, et al. Study of antimicrobial effects of clarithromycin loaded PLGA nanoparticles against clinical strains of Helicobacter pylori. Drug Res (Stuttg). 2016;66(1):41–45.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515.
   PubMed Web of Science ®Google Scholar
• Kroll AV, Fang RH, Zhang L. Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjug Chem. 2016;28(1):23–32.
   PubMed Web of Science ®Google Scholar
• Mody VV, Gupta H. Introduction to metallic nanoparticles. J Pharm Bioallied Sci. 2010;2(4):282.
   PubMedGoogle Scholar
• Luo J, Chan W-B, Wang L, et al. Probing interfacial interactions of bacteria on metal nanoparticles and substrates with different surface properties. Int J Antimicrob Agents. 2010;36(6):549–556.
   PubMed Web of Science ®Google Scholar
• Lee D, Cohen RE, Rubner MF. Antibacterial properties of Ag nanoparticle loaded multilayers and formation of magnetically directed antibacterial microparticles. Langmuir. 2005;21(21):9651–9659.
   PubMed Web of Science ®Google Scholar
• Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013;65(13–14):1803–1815.
   PubMed Web of Science ®Google Scholar
• Amin M, Hameed S, Ali A, et al. Green synthesis of silver nanoparticles: structural features and in vivo and in vitro therapeutic effects against Helicobacter pylori induced gastritis. Bioinorg Chem Appl. 2014;2014.
   PubMedGoogle Scholar
• Amin M, Anwar F, Janjua MRSA, et al. Green synthesis of silver nanoparticles through reduction with Solanum xanthocarpum L. berry extract: characterization, antimicrobial and urease inhibitory activities against Helicobacter pylori. Int J Mol Sci. 2012;13(8):9923–9941.
   PubMed Web of Science ®Google Scholar
• Dreaden EC, Alkilany AM, Huang X, et al. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev. 2012;41(7):2740–2779.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhao Y, Tian Y, et al. The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. Biomaterials. 2012;33(7):2327–2333.
   Web of Science ®Google Scholar
• Gopinath V, Priyadarshini S, MubarakAli D, et al. Anti-Helicobacter pylori, cytotoxicity and catalytic activity of biosynthesized gold nanoparticles: multifaceted application. Arabian journal of chemistry. 2016.
   Google Scholar
• Li JJ, Hartono D, Ong C-N, et al. Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials. 2010;31(23):5996–6003.
   PubMed Web of Science ®Google Scholar
• Pan Y, Neuss S, Leifert A, et al. Size‐dependent cytotoxicity of gold nanoparticles. Small. 2007;3(11):1941–1949.
   Web of Science ®Google Scholar
• Lopes TS, Alves GG, Pereira MR, et al. Advances and potential application of gold nanoparticles in nanomedicine. J Cell Biochem. 2019.
   Web of Science ®Google Scholar
• Xie Y, He Y, Irwin PL, et al. Antibacterial activity and mechanism of action of zinc oxide nanoparticles against Campylobacter jejuni. Appl Environ Microbiol. 2011;77(7):2325–2331.
   Web of Science ®Google Scholar
• Reddy KM, Feris K, Bell J, et al. Selective toxicity of zinc oxide nanoparticles to prokaryotic and eukaryotic systems. Appl Phys Lett. 2007;90(21):213902.
   Web of Science ®Google Scholar
• Chakraborti S, Bhattacharya S, Chowdhury R, et al. The molecular basis of inactivation of metronidazole-resistant Helicobacter pylori using polyethyleneimine functionalized zinc oxide nanoparticles. PLoS One. 2013;8(8):e70776.
   PubMed Web of Science ®Google Scholar
• Ahamed M, AlSalhi MS, Siddiqui M. Silver nanoparticle applications and human health. Clin Chim Acta. 2010;411(23–24):1841–1848.
   PubMed Web of Science ®Google Scholar
• Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27(1):76–83.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Jeong J-K, Han JW, et al. Multidimensional effects of biologically synthesized silver nanoparticles in Helicobacter pylori, Helicobacter felis, and human lung (L132) and lung carcinoma A549 cells. Nanoscale Res Lett. 2015;10(1):35.
   PubMedGoogle Scholar
• Saravanakumar K, Chelliah R, MubarakAli D, et al. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori. Sci Rep. 2019;9(1):5787.
   PubMedGoogle Scholar
• Prasad A, Baker S, Nagendra Prasad MN, et al. Phytogenic synthesis of silver nanobactericides for anti-biofilm activity against human pathogen H. pylori. SN Appl Sci. 2019;1(4):341.
   Web of Science ®Google Scholar
• Chen R, Cheng G, So MH, et al. Bismuth subcarbonate nanoparticles fabricated by water-in-oil microemulsion-assisted hydrothermal process exhibit anti-Helicobacter pylori properties. Mater Res Bull. 2010;45(5):654–658.
   Web of Science ®Google Scholar
• Nazari P, Dowlatabadi-Bazaz R, Mofid MR, et al. The antimicrobial effects and metabolomic footprinting of carboxyl-capped bismuth nanoparticles against Helicobacter pylori. Appl Biochem Biotechnol. 2014;172(2):570–579.
   PubMed Web of Science ®Google Scholar
• Alavi M, Karimi N, Valadbeigi T. Antibacterial, antibiofilm, antiquorum sensing, antimotility, and antioxidant activities of green fabricated Ag, Cu, TiO2, ZnO, and Fe3O4 NPs via protoparmeliopsis muralis lichen aqueous extract against multi-drug-resistant bacteria. ACS Biomater Sci Eng. 2019;5(9):4228–4243.
   PubMed Web of Science ®Google Scholar
• Baptista PV, McCusker MP, Carvalho A, et al. Nano-strategies to fight multidrug resistant bacteria—“A Battle of the Titans”. Front Microbiol. 2018;9.
   PubMedGoogle Scholar
• Alavi M, Rai M. Recent advances in antibacterial applications of metal nanoparticles (MNPs) and metal nanocomposites (MNCs) against multidrug-resistant (MDR) bacteria. Expert Rev Anti Infect Ther. 2019;17(6):419–428.
   PubMed Web of Science ®Google Scholar
• Raghupathi KR, Koodali RT, Manna AC. Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles. Langmuir. 2011;27(7):4020–4028.
   PubMed Web of Science ®Google Scholar
• Ansari MA, Khan HM, Khan AA, et al. Interaction of silver nanoparticles with Escherichia coli and their cell envelope biomolecules. J Basic Microbiol. 2014;54(9):905–915.
   Web of Science ®Google Scholar
• Joost U, Juganson K, Visnapuu M, et al. Photocatalytic antibacterial activity of nano-TiO2 (anatase)-based thin films: effects on Escherichia coli cells and fatty acids. J Photochem Photobiol B Biol. 2015;142:178–185.
   PubMed Web of Science ®Google Scholar
• Li YF, Chen C. Fate and toxicity of metallic and metal‐containing nanoparticles for biomedical applications. Small. 2011;7(21):2965–2980.
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1–20):(1–2): p.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–3666.
   Web of Science ®Google Scholar
• Gao W, Thamphiwatana S, Angsantikul P, et al. Nanoparticle approaches against bacterial infections. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(6):532–547.
   Web of Science ®Google Scholar
• Zhang L, Radovic-Moreno A, Alexis F, et al. Codelivery of hydrophobic and hydrophilic drugs from nanoparticle–aptamer bioconjugates. Chem Med Chem. 2007;2(9):1268–1271.
   Google Scholar
• Chan JM, Zhang L, Yuet KP, et al. PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30(8):1627–1634.
   PubMed Web of Science ®Google Scholar
• Valizadeh H, Mohammadi G, Ehyaei R, et al. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Die Pharmazie- Int J Pharm Sci. 2012;67(1):63–68.
   Google Scholar
• Pimienta C, Chouinard F, Labib A, et al. Effect of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow. Int J Pharm. 1992;80(1–3):1–8.
   Google Scholar
• Fontana G, Licciardi M, Mansueto S, et al. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials. 2001;22(21):2857–2865.
   PubMed Web of Science ®Google Scholar
• Donev R. Protein and peptide nanoparticles for drug delivery. Vol. 98. Academic Press; 2015;294–317.
   Google Scholar
• Ramteke S, Jain NK. Clarithromycin-and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori. J Drug Target. 2008;16(1):65–72.
   PubMed Web of Science ®Google Scholar
• Arangoa M, Ponchel G, Orecchioni AM, et al. Bioadhesive potential of gliadin nanoparticulate systems. Eur J Pharm Sci. 2000;11(4):333–341.
   PubMed Web of Science ®Google Scholar
• Umamaheshwari R, Jain N. Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target. 2003;11(7):415–424.
   PubMed Web of Science ®Google Scholar
• Rudnik E Compostable polymer properties and packaging applications. In: Plastic Films in Food Packaging. Elsevier; 2013. p. 217–248.
   Google Scholar
• Pan-In P, Banlunara W, Chaichanawongsaroj N, et al. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. Carbohydr Polym. 2014;109:22–27.
   PubMed Web of Science ®Google Scholar
• Xiong M-H, Bao Y, Yang X-Z, et al. Delivery of antibiotics with polymeric particles. Adv Drug Deliv Rev. 2014;78:63–76.
   PubMed Web of Science ®Google Scholar
• Neouze M-A, Schubert U. Surface modification and functionalization of metal and metal oxide nanoparticles by organic ligands. Monatshefte Für Chemie-Chemical Monthly. 2008;139(3):183–195.
   Google Scholar
• Baraton M-I. Synthesis, functionalization and surface treatment of nanoparticles. Amer Scientific Pub; 2003;161–171.
   Google Scholar
• Moon J, Shul YG, Han HS, et al. A study on UV-curable adhesives for optical pick-up: I. Photo-initiator effects. Int J Adhes Adhes. 2005;25(4):301–312.
   Web of Science ®Google Scholar
• Luo M, Jia -Y-Y, Jing Z-W, et al. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori. Colloids Surf B Biointerfaces. 2018;164:11–19.
   PubMed Web of Science ®Google Scholar
• Lin Y-H, Tsai S-C, Lai C-H, et al. Genipin-cross-linked fucose–chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials. 2013;34(18):4466–4479.
   PubMed Web of Science ®Google Scholar
• Lin Y-H, Lin J-H, Chou S-C, et al. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study. Nanomedicine. 2015;10(1):57–71.
   PubMed Web of Science ®Google Scholar
• Arif M, Dong Q-J, Raja MA, et al. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori. Mater Sci Eng C. 2018;83:17–24.
   PubMed Web of Science ®Google Scholar
• Arora S, Bisen G, Budhiraja R. Mucoadhesive and muco-penetrating delivery systems for eradication of Helicobacter pylori. Asian J Pharm (AJP). 2014;6(1):18–30.
   Google Scholar
• Narain A, Asawa S, Chhabria V, et al. Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine. 2017;12(21):2677–2692.
   PubMed Web of Science ®Google Scholar
• Luk BT, Zhang L. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release. 2015;220:600–607.
   PubMed Web of Science ®Google Scholar
• Pang Z, Hu C-MJ, Fang RH, et al. Detoxification of organophosphate poisoning using nanoparticle bioscavengers. ACS Nano. 2015;9(6):6450–6458.
   PubMed Web of Science ®Google Scholar
• Wei X, Gao J, Fang RH, et al. Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia. Biomaterials. 2016;111:116–123.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760.
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Nat Acad Sci. 2011;108(27):10980–10985.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao W, Fang RH, et al. Synthesis of nanogels via cell membrane templated polymerization. Small. 2015;11(34):4309–4313.
   Web of Science ®Google Scholar
• Luk BT, Fang RH, Hu C-MJ, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics. 2016;6(7):1004–1011.
   PubMed Web of Science ®Google Scholar
• Rao L, Dávila N, Ge N, et al. Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology. 2016;27(8):085106.
   PubMed Web of Science ®Google Scholar
• Xuan M, Shao J, Dai L, et al. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016;8(15):9610–9618.
   PubMed Web of Science ®Google Scholar
• Sun H, Su J, Meng Q, et al. Cancer cell biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater. 2016;28(43):9581–9588.
   PubMed Web of Science ®Google Scholar
• Angsantikul P, Thamphiwatana S, Zhang Q, et al. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against helicobacter pylori infection. Adv Ther. 2018;1(2):1800016.
   Google Scholar
• Gao W, Zhang L. Coating nanoparticles with cell membranes for targeted drug delivery. J Drug Target. 2015;23(7–8):619–626.
   PubMed Web of Science ®Google Scholar
• Gao C, Lin Z, Jurado-Sánchez B, et al. Stem cell membrane coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small. 2016;12(30):4056–4062.
   PubMed Web of Science ®Google Scholar
• Gao W, Fang RH, Thamphiwatana S, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett. 2015;15(2):1403–1409.
   PubMed Web of Science ®Google Scholar